Afami-cel is made by collecting a patient’s T-cells, genetically modifying them and infusing them back into the patient, according to an Aug. 27 National Cancer Institute news release. The treatment has been approved for people with metastatic synovial sarcoma who have been treated with chemotherapy and whose tumors are positive for the presence of MAGE-A4 and a certain HLA proteins.
In a trial of 44 patients, 43% saw a shrinkage in their tumors that lasted an average of six months.
This T-cell therapy is similar to CAR-T cell therapies already approved by the FDA, according to the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
